Morling Financial Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-236
Closed -$283K – 152
2026
Q2
$283K Buy
236
+3
+1% +$3.06K 0.08% 62
2026
Q1
$214K Sell
233
-4
-2% -$4.06K 0.07% 69
2025
Q4
$255K Buy
+237
New +$227K 0.08% 66
2025
Q2
– Sell
-567
Closed -$468K – 115
2025
Q1
$468K Buy
567
+301
+113% +$250K 0.16% 46
2024
Q4
$205K Buy
266
+12
+5% +$9.9K 0.07% 69
2024
Q3
$225K Buy
254
+1
+0.4% +$899 0.09% 64
2024
Q2
$229K Sell
253
-182
-42% -$146K 0.1% 55
2024
Q1
$338K Sell
435
-117
-21% -$83.3K 0.19% 46
2023
Q4
$322K Buy
552
+2
+0.4% +$1.17K 0.26% 43
2023
Q3
$295K Sell
550
-133
-19% -$68.5K 0.29% 42
2023
Q2
$320K Sell
683
-78
-10% -$32.7K 0.31% 40
2023
Q1
$261K Buy
761
+24
+3% +$8.09K 0.28% 44
2022
Q4
$270K Sell
737
-92
-11% -$32.6K 0.34% 41
2022
Q3
$268K Hold
829
– – 0.37% 39
2022
Q2
$269K Buy
829
+2
+0.2% +$600 0.35% 40
2022
Q1
$237K Hold
827
– – 0.3% 44
2021
Q4
$228K Buy
+827
New +$210K 0.22% 43

Other funds holding LLY

Morling Financial Advisors's LLY Position: Q3 2026 in Review

Morling Financial Advisors sold out of Eli Lilly (LLY) in Q3 2026, closing a stake of 236 shares — an estimated $283K sold.

Morling Financial Advisors first reported a position in LLY in Q4 2021 and held it in 17 quarters. The position peaked at $468K in Q1 2025. 4,599 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Morling Financial Advisors reported no remaining Eli Lilly position as of Q3 2026 after selling out during the quarter.
  • Morling Financial Advisors sold 236 Eli Lilly shares in Q3 2026, an estimated $283K.
  • Morling Financial Advisors first reported a position in Eli Lilly in Q4 2021 and held it in 17 quarters.
  • Morling Financial Advisors's Eli Lilly position peaked at $468K in Q1 2025.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Morling Financial Advisors's 13F filing for Q3 2026, filed 28 Oct 2026.